BioMarin Pharmaceutical Inc. (BMRN) SEC Filings & Earnings Calls

Acquisition charges reduce earnings; guidance to be updated.

“$320M full-year charges; EPS impact $1.55.”

Royalty revenue dependent on commercial success of TransCon CNP; no guaranteed minimum payments.

“royalty equal to 20% of annual net sales ... until May 2030”

Pipeline setback reduces future revenue potential from VOXZOGO in Noonan syndrome.

“Discontinuation of development for Noonan syndrome indication.”

Integration risk: absorbing Alesta's operations and pipeline.

“Alesta is now a wholly owned subsidiary of BioMarin” · word for word

Dependence on Ascendis commercialization success and sales of licensed products; potential for lower-than-expected royalties if sales underperform.

“actual sales of Licensed Products; BioMarin’s ability to enforce the Term Sheet or the Agreement”

Integration risk and milestone payment obligations; potential dilution from transaction costs

“Transaction expected to close in Q3 2026; modestly dilutive impact on 2026 financial results”

Integration risk from Amicus acquisition

“We may not realize the anticipated benefits from the Amicus Acquisition or accurately forecast the future performance of the combined company.” · word for word

Increased leverage and interest expense

“Interest expense $63,295 thousand vs $2,679 thousand in Q2 2025”

Pipeline dependency on VOXZOGO; BMN 401 discontinued after missing endpoints.

“BMN 401 did not meet one of its two co-primary endpoints... discontinue development of BMN 401 across all indications.” · word for word

Potential dilution from increased share reserve, but standard for biotech equity compensation.

“7,650,000 additional shares authorized under equity plan”

Acquisition Integration Risk

“We may not realize the anticipated benefits from the Amicus Acquisition or accurately forecast the future performance of the combined company.” · word for word

Macroeconomic and Tariff Risk

“Conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, geopolitical instability, wars and military conflicts, impact of new or increased tariffs and escalating trade tensions, regulatory uncertainty, and supply chain disruptions, could impact our global revenue sourc” · word for word

Product Concentration Risk

“Customer A 15%, Customer B 11%, Customer C 10% of net product revenues; one customer accounted for 20% of accounts receivable.”

DOJ Investigation Risk

“The Company received a subpoena from the U.S. Department of Justice (DOJ) requesting that the Company produce certain documents regarding sponsored testing programs relating to VIMIZIM and NAGLAZYME.” · word for word

Integration risk from Amicus acquisition; higher SG&A and cost of sales pressuring net income.

“higher Selling, General & Administrative (SG&A) spend primarily due to incremental administrative costs related to ongoing support of corporate initiatives and pre-close costs for Amicus acquisition” · word for word

ROCTAVIAN voluntary withdrawal reduces revenue stream.

“lower ROCTAVIAN revenue attributed to voluntary withdrawal of the product from the market” · word for word

High leverage from acquisition financing; $2.8B in new debt increases financial risk.

“Credit Agreement provides for $2.0B Term Loan B, $800M Term Loan A, $600M revolver; secured by substantially all assets.”

Integration risk from acquiring Amicus Therapeutics; potential operational and cultural challenges.

“Merger of Merger Sub with and into Amicus, with Amicus surviving as wholly owned subsidiary.”

Minimal new risk; regulatory clearance reduces deal risk.

“French FDI clearance received; final condition satisfied.”

Safety events (SCFE) in VOXZOGO trials for new indications; potential regulatory scrutiny and pipeline delay.

“several slipped capital femoral epiphysis (SCFE) events in two ongoing investigator-sponsored trials” · word for word

Pipeline setback for VOXZOGO expansion beyond achondroplasia; reduces addressable market opportunity.

“discontinue dosing and enrollment in its Phase 2 trials for VOXZOGO in Turner Syndrome, SHOX-deficiency and Aggrecan (ACAN)-deficiency” · word for word

Acquisition integration risk

“In December 2025, in connection with the pending acquisition of Amicus, we entered into the Commitment Letter... to provide us with debt financing in an aggregate principal amount of up to approximately $3.7 billion.” · word for word

Debt service risk

“Our $600.0 million (undiscounted) of total convertible debt as of December 31, 2025... will impact our liquidity due to semi-annual cash interest payments and repayment of the principal amount in cash at maturity in May 2027 if not converted.” · word for word

Acquisition integration risk: Amicus acquisition expected to close in Q2'26, subject to regulatory and stockholder approvals.

“expected to close in Q2'26, subject to regulatory clearances, approval by the stockholders of Amicus and other customary closing conditions” · word for word

Dependence on VOXZOGO for growth, with OUS markets driving majority of revenue, exposing to international regulatory and market risks.

“Markets outside of the U.S. (OUS) drove approximately 73% of VOXZOGO revenue in full-year 2025” · word for word

Acquisition completion risk: If acquisition not completed by Dec 19, 2026, BioMarin must redeem all notes at 100% plus accrued interest.

“In the event that the Acquisition is not completed on or prior to December 19, 2026...BioMarin will be required to redeem all of the Notes at a redemption price equal to 100% of the initial issue price” · word for word

Increased leverage: Significant debt taken on to finance acquisition, with customary covenants restricting additional debt, dividends, and asset sales.

“The indenture governing the Notes contains customary covenants that...restrict...the ability of each of BioMarin and its subsidiaries to incur additional debt, pay dividends, make certain other restricted payments” · word for word

Acquisition of Amicus Therapeutics carries integration risk and significant debt burden ($3.65B in new debt).

“Notes offering $850M, Term Loan B $2B, Term Loan A $800M, revolver $600M; supplemental risk factors filed.”

Preliminary revenue estimates are unaudited and subject to adjustment upon completion of normal quarterly closing procedures.

“Estimated total revenues ~$3.2 billion (unaudited); subject to completion of normal quarterly and annual accounting procedures.”

If acquisition is not completed by December 19, 2026, BioMarin must redeem the notes at 100% plus accrued interest, creating refinancing risk.

“In the event that the Acquisition is not completed on or prior to December 19, 2026... BioMarin will be required to redeem all of the Notes.” · word for word

ROCTAVIAN write-down indicates commercial failure; future revenue from this product uncertain.

“Asset write-down of $230-260M for ROCTAVIAN.”

Acquisition integration risk: Amicus Therapeutics acquisition may not deliver expected synergies.

“Forward-looking statements mention risks related to acquisition integration.”

Preliminary results subject to change; final audited results may differ.

“Preliminary unaudited financial information subject to completion of closing procedures.”

Pipeline setback reduces future revenue optionality and may signal R&D execution risk.

“Discontinuation of BMN 349, an oral therapeutic for AATD-associated liver disease.”

Integration risk and debt leverage

“Transaction subject to regulatory clearances and Amicus stockholder approval; targeting gross leverage <2.5x within two years”

DOJ investigation into VIMIZIM/NAGLAZYME sponsored testing programs

“The Company received a subpoena from the U.S. Department of Justice (DOJ) requesting that the Company produce certain documents regarding sponsored testing programs relating to VIMIZIM and NAGLAZYME.” · word for word

Customer concentration risk

“Three customers accounted for 37% of net product revenues in Q3 2025 (33% in Q3 2024).”

Foreign exchange exposure

“As of September 30, 2025, the Company expects to reclassify unrealized losses of $28.6 million from AOCI to earnings over the next twelve months.” · word for word

IPR&D charge from Inozyme acquisition impacts GAAP profitability; non-GAAP income decline.

“$221 million IPR&D charge; Non-GAAP income down 88% YoY.”

Divestiture of ROCTAVIAN may indicate strategic shift or product underperformance.

“Pursuing options to divest ROCTAVIAN; removing from portfolio.”